Autoimmune liver disease in children

Area of Science:

• Pediatric Hepatology
• Autoimmune Diseases
• Immunology

Background:

• Autoimmune liver disease (AILD) in children can lead to severe outcomes like cirrhosis and liver failure if not promptly addressed.
• Early diagnosis and management are crucial for improving patient prognosis.

Purpose of the Study:

• To prospectively analyze pediatric patients with liver disease to identify autoimmune etiology.
• To evaluate the outcomes of treatment for autoimmune liver disease in children.

Main Methods:

• Patients underwent comprehensive liver disease evaluation, including serological markers for autoimmune hepatitis (ANA, SMA, anti-LKM-1) and viral hepatitis.
• Diagnosis of AILD was based on positive autoantibodies and exclusion of other etiologies, adhering to International Autoimmune Hepatitis Group criteria.
• Diagnosed AILD cases were treated with immunosuppressive drugs, primarily oral prednisolone and azathioprine.

Main Results:

• Autoimmune liver disease represented 3.9% of chronic liver disease cases in the pediatric cohort.
• Treatment with immunosuppressive therapy resulted in remission in 4 out of 6 diagnosed AILD patients.
• Two patients achieved remission and were weaned off therapy; one developed superimposed acute Hepatitis E virus (HEV) infection.

Conclusions:

• Autoimmune liver disease, though infrequent in children, is a significant diagnosis that responds well to immunosuppressive treatment.
• Achieving remission is possible with timely intervention, highlighting the importance of screening for AILD in pediatric liver disease.
• The risk of superimposed viral hepatitis, such as HEV, exists even in patients with autoimmune liver disease in endemic regions.